9-ING-41 in Patients With Advanced Cancers (NCT03678883) | Clinical Trial Compass
Active — Not RecruitingPhase 2
9-ING-41 in Patients With Advanced Cancers
United States350 participantsStarted 2019-01-04
Plain-language summary
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Is able to understand and voluntarily sign a written informed consent and is willing and able to comply with the protocol requirements including scheduled visits, treatment plan, laboratory tests and other study procedures.
✓. Is aged ≥ 18 years
✓. Has pathologically confirmed advanced or metastatic malignancy characterized by one or more of the following:
✓. Patient is intolerant of existing therapy(ies) known to provide clinical benefit for their condition
✓. Malignancy is refractory to existing therapy(ies) known to potentially provide clinical benefit
✓. Malignancy has relapsed after standard therapy
✓. Malignancy for which there is no standard therapy that improves survival by at least 3 months
✓. Has evaluable tumor(s) by standard radiological and/or laboratory assessments as applicable to their malignancy - in Part 3, patients with solid tumors must have least 1 measurable lesion per response evaluation criteria in solid tumors (RECIST) v1.1 criteria, measured preferably by computed tomography (CT) scan or magnetic resonance image (MRI). In the case of patients with glioblastoma multiforme (GBM) or other central nervous system (CNS) tumors, the tumor must be measurable, defined as a clearly enhancing tumor with at two perpendicular diameters at entry equal or superior to 1cm.
Exclusion criteria
✕. Is pregnant or lactating
✕. Is known to be hypersensitive to any of the components of 9-ING-41 or to the excipients used in its formulation
What they're measuring
1
Parts 1/2: Number of participants with treatment-related adverse events as assessed by CTCAE v4.03
✕. Has not recovered from clinically significant toxicities as a result of prior anticancer therapy, except alopecia and infertility. Recovery is defined as ≤ Grade 2 CTCAE Version 4.03
✕. Has significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, or stroke within 6 months of the first dose of 9-ING-41, or cardiac arrhythmia requiring medical treatment detected at screening
✕. Has had a myocardial infarction within 12 weeks of the first dose of 9-ING-41 or has electrocardiogram (ECG) abnormalities that are deemed medically relevant by the investigator or study medical coordinator
✕. Has known symptomatic rapidly progressive brain metastases or leptomeningeal involvement as assessed by CT scan or MRI. Patients with stable asymptomatic brain metastases or leptomeningeal disease or slowly progressive disease are eligible provided that they have not required new treatments for this disease in a 28-day period before the first dose of study drug, and anticonvulsants and steroids are at a stable dose for a period of 14 days prior to the first dose of study drug
✕. Has had major surgery (not including placement of central lines) within 7 days prior to study entry or is planned to have major surgery during the course of the study (major surgery may be defined as any invasive operative procedure in which an extensive resection is performed, e.g. a body cavity is entered, organs are removed, or normal anatomy is altered. In general, if a mesenchymal barrier is opened (pleural cavity, peritoneum, meninges), the surgery is considered major)
✕. Has any medical and/or social condition which, in the opinion of the investigator or study medical coordinator would preclude study participation